ProQR (PRQR) CSO details sizeable option grants and share stake

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.

It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from $0.6700 to $15.7800, with expiration dates between 2026-12-31 and 2035-12-31. Footnotes explain that some options are fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.

The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Platenburg Gerardus Johannes

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	824,388	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	12/31/2026	Ordinary Shares	61,453	$4.9	D
Share Option (Right to Buy)	(1)	12/31/2027	Ordinary Shares	71,409	$3.3	D
Share Option (Right to Buy)	(1)	12/31/2028	Ordinary Shares	17,878	$15.78	D
Share Option (Right to Buy)	(1)	12/31/2029	Ordinary Shares	141,369	$9.91	D
Share Option (Right to Buy)	(1)	12/31/2030	Ordinary Shares	79,033	$4.2	D
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	77,353	$1.02	D
Share Option (Right to Buy)	(1)	04/30/2032	Ordinary Shares	172,603	$0.67	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	152,000	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	164,715	$1.98	D
Share Option (Right to Buy)	(4)	12/31/2034	Ordinary Shares	159,358	$2.65	D
Share Option (Right to Buy)	(5)	12/31/2035	Ordinary Shares	186,139	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does ProQR (PRQR) Chief Scientific Officer Platenburg report in this Form 3?

He reports his initial beneficial ownership in ProQR, including direct Ordinary Share holdings and a series of share options. The filing is a baseline disclosure of his equity position, not a record of new purchases or sales.

How many ProQR (PRQR) Ordinary Shares does Platenburg directly hold?

Platenburg reports direct ownership of 824,388 Ordinary Shares of ProQR. This figure represents his post-reporting position in common equity and is separate from his various option grants to acquire additional Ordinary Shares in the future.

What share options are disclosed for Platenburg in ProQR (PRQR)?

He lists multiple “Share Option (Right to Buy)” positions over Ordinary Shares, with exercise prices such as $4.9000, $3.3000, and $0.6700, and expiration dates from 2026-12-31 out to 2035-12-31, all held with direct ownership.

How do Platenburg’s ProQR (PRQR) options vest according to the Form 3 footnotes?

Footnotes state certain options are fully vested, while others vest 25% on January 1 of 2024, 2025, 2026, or 2027. The remaining 75% vests in 12 substantially equal quarterly installments, contingent on his continuous service.

Does this ProQR (PRQR) Form 3 show any insider buying or selling by Platenburg?

No, it does not show insider buying or selling. The transaction records are classified as holdings, and the transaction summary indicates zero buys, zero sells, and no option exercises, gifts, or tax-withholding dispositions in this disclosure.

What does the derivative summary reveal about Platenburg’s ProQR (PRQR) option position?

The derivative summary lists unexercised “Share Option (Right to Buy)” positions over specified numbers of Ordinary Shares, with defined exercise prices and expiration dates. It reflects option awards he continues to hold rather than recent exercises or sales.